FNY Investment Advisers’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-700
Closed -$106K 989
2026
Q1
$106K Buy
+700
New +$107K 0.05% 270
2024
Q4
Sell
-5,000
Closed -$575K 856
2024
Q3
$575K Buy
+5,000
New +$567K 0.28% 92
2023
Q4
Sell
-4,000
Closed -$386K 705
2023
Q3
$386K Buy
+4,000
New +$406K 0.23% 63
2022
Q4
Sell
-5,380
Closed -$408K 677
2022
Q3
$408K Buy
+5,380
New +$446K 0.28% 61
2022
Q1
Sell
-10,000
Closed -$874K 859
2021
Q4
$874K Sell
10,000
-22,400
-69% -$1.86M 0.47% 51
2021
Q3
$2.65M Buy
+32,400
New +$2.91M 1.23% 18
2021
Q2
Sell
-3,000
Closed -$256K 905
2021
Q1
$256K Sell
3,000
-8,950
-75% -$803K 0.1% 154
2020
Q4
$1.13M Buy
11,950
+6,950
+139% +$607K 0.31% 82
2020
Q3
$434K Sell
5,000
-11,900
-70% -$1.03M 0.18% 114
2020
Q2
$1.48M Buy
+16,900
New +$1.46M 0.86% 27
2020
Q1
Sell
-20,293
Closed -$1.92M 701
2019
Q4
$1.92M Buy
+20,293
New +$1.82M 0.6% 30
2019
Q2
Sell
-14,887
Closed -$1.28M 1082
2019
Q1
$1.28M Buy
+14,887
New +$1.2M 0.44% 36

Other funds holding NVS

FNY Investment Advisers's NVS Position: Q2 2026 in Review

FNY Investment Advisers sold out of Novartis (NVS) in Q2 2026, closing a stake of 700 shares — an estimated $106K sold.

FNY Investment Advisers first reported a position in NVS in Q1 2019 and held it in 12 quarters. The position peaked at $2.65M in Q3 2021. 779 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • FNY Investment Advisers reported no remaining Novartis position as of Q2 2026 after selling out during the quarter.
  • FNY Investment Advisers sold 700 Novartis shares in Q2 2026, an estimated $106K.
  • FNY Investment Advisers first reported a position in Novartis in Q1 2019 and held it in 12 quarters.
  • FNY Investment Advisers's Novartis position peaked at $2.65M in Q3 2021.
  • 779 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.